id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1986-V-0022-0007,FDA,FDA-1986-V-0022,Variance Approval Letter from FDA CDRH to California Technical Associates,Other,Approval for Variance (VRA),1994-12-30T05:00:00Z,1994,12,,,2023-01-18T18:31:29Z,,0,0,090000648050dd41
FDA-1988-N-0028-0002,FDA,FDA-1988-N-0028,FDA,Notice,NAD-Notice of Availability of Data,1994-12-27T05:00:00Z,1994,12,1994-12-27T05:00:00Z,1995-03-15T04:59:59Z,2008-05-30T22:53:14Z,,0,0,0900006480476632
FDA-1994-P-0049-0003,FDA,FDA-1994-P-0049,HFA-305 to Action on Smoking and Health (ASH),Other,ACK-Acknowledgement Letter,1994-12-23T05:00:00Z,1994,12,,,2008-05-16T23:21:33Z,,0,0,09000064804ffa14
FDA-1991-N-0041-0004,FDA,FDA-1991-N-0041,Medical Devices; Substantial Equivalence; 510(k) Summaries and 510(k) Statements; Class III Summaries; Confidentiality of Information,Notice,Notice of Final Rule,1994-12-20T05:00:00Z,1994,12,,,2023-09-01T14:49:14Z,94-30422,0,0,090000648052a20f
FDA-1994-F-0010-0001,FDA,FDA-1994-F-0010,"Roquette America, Inc.; Filing of Food Additive Petition",Notice,Notice of Filing,1994-12-15T05:00:00Z,1994,12,1994-12-15T05:00:00Z,1995-01-13T04:59:59Z,2024-05-28T14:03:33Z,94-30585,0,0,09000064804fc65b
FDA-1994-F-0010-0005,FDA,FDA-1994-F-0010,"Environmental Assessment from Roquette America, Inc.",Supporting & Related Material,Environmental Assessment,1994-12-15T05:00:00Z,1994,12,,,2024-05-28T14:18:41Z,,0,0,09000064804fc664
FDA-1981-N-0012-0010,FDA,FDA-1981-N-0012,"HFA-305 to Caprice-Greystoke, Ltd",Other,ACK-Acknowledgement Letter,1994-12-14T05:00:00Z,1994,12,,,2008-05-30T22:53:23Z,,0,0,09000064805ae8d5
FDA-1981-N-0043-0004,FDA,FDA-1981-N-0043,Marketing of Over-the-Counter Pediculicide Drug Products; Background Documents; Availability,Notice,Notice of Data Availability,1994-12-13T05:00:00Z,1994,12,,,2021-03-15T13:05:51Z,94-29987,0,0,09000064805af2eb
FDA-1993-N-0043-0002,FDA,FDA-1993-N-0043,Adverse Experience Reporting Requirements for Human Drug and Licensed Biological Products; Correction,Notice,Correction,1994-12-05T05:00:00Z,1994,12,,,2024-04-29T14:48:41Z,,0,0,09000064804fc3bb
FDA-1982-P-0018-0388,FDA,FDA-1982-P-0018,Acknowledgment Letter from FDA Dockets Management Branch to Edward R. Hutchinson,Other,Acknowledgement Letter/Receipt,1994-12-01T05:00:00Z,1994,12,,,2025-01-07T12:57:06Z,,0,0,090000648050e72b
FDA-1994-N-0035-0003,FDA,FDA-1994-N-0035,Methods of the Allergenics Products Testing Laboratory,Supporting & Related Material,BKG-Background Material,1994-11-30T05:00:00Z,1994,11,,,2008-05-16T23:15:32Z,,0,0,09000064804fd698
FDA-1994-N-0035-0002,FDA,FDA-1994-N-0035,Methods of the Allergenics Products Testing Laboratory,Supporting & Related Material,BKG-Background Material,1994-11-30T05:00:00Z,1994,11,,,2008-05-16T23:15:32Z,,0,0,09000064804fd68e
FDA-1994-N-0035-0001,FDA,FDA-1994-N-0035,Methods of the Allergenic Products Testing Laboratory; Availability,Notice,Notice of Availability,1994-11-30T05:00:00Z,1994,11,,,2024-10-04T20:23:52Z,,0,0,09000064804fd68b
FDA-1975-N-0012-0001,FDA,FDA-1975-N-0012,Draft FRN - Topical Antimicrobial Drug Products for Over-the Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products; Extension of Comment and New Data Periods,Proposed Rule,Notice of Extension,1994-11-28T05:00:00Z,1994,11,1994-11-28T05:00:00Z,2019-04-04T03:59:59Z,2019-04-03T01:03:54Z,FR Doc. 94- 28063,0,0,09000064805c1908
FDA-1994-P-0045-0001,FDA,FDA-1994-P-0045,Acknowledgment Letter from FDA DMB to Medical Gases Committee,Other,Acknowledgement Letter/Receipt,1994-11-28T05:00:00Z,1994,11,,,2024-07-01T14:53:49Z,,0,0,09000064804ff6c5
FDA-1994-P-0042-0001,FDA,FDA-1994-P-0042,"Acknowledgment Letter from FDA DMB to Fox, Bennett & Turner",Other,Acknowledgement Letter/Receipt,1994-11-22T05:00:00Z,1994,11,,,2024-06-18T15:39:19Z,,0,0,09000064804ff3dd
FDA-1992-N-0007-0003,FDA,FDA-1992-N-0007,FDA,Notice,N-Notice,1994-11-17T05:00:00Z,1994,11,1994-11-17T05:00:00Z,1995-02-17T04:59:59Z,2008-05-16T23:31:45Z,,0,0,0900006480525b33
FDA-1994-N-0037-0002,FDA,FDA-1994-N-0037,FDA,Notice,NEC-Notice of Extension,1994-11-16T05:00:00Z,1994,11,1994-11-16T05:00:00Z,1995-02-14T04:59:59Z,2008-05-16T23:15:39Z,,0,0,09000064804fd7ff
FDA-1993-N-0043-0001,FDA,FDA-1993-N-0043,Adverse Experience Reporting Requirements for Human Drug and Licensed Biological Products,Notice,NPR-Notice of Proposed Rule-Making,1994-11-15T05:00:00Z,1994,11,1994-11-15T05:00:00Z,1995-01-26T04:59:59Z,2024-04-29T14:42:48Z,,0,0,09000064804fc3b4
FDA-1994-M-0011-0001,FDA,FDA-1994-M-0011,"Exogen Inc., Premarket Approval of Sonic Accelerated Fracture Healing System (SAFHS)",Notice,Notice of Approval,1994-11-14T05:00:00Z,1994,11,1994-11-14T05:00:00Z,1994-12-10T04:59:59Z,2024-06-07T14:52:20Z,94-27222,0,0,09000064804fc6e1
FDA-1994-N-0030-0001,FDA,FDA-1994-N-0030,FDA,Notice,Notice of Opportunity of Hearing,1994-11-14T05:00:00Z,1994,11,1994-11-14T05:00:00Z,1994-12-10T04:59:59Z,2024-12-07T20:22:46Z,,0,0,09000064804fd3d1
FDA-1994-E-0047-0001,FDA,FDA-1994-E-0047,Determination of Regulatory Review Period for Purposes of Patent Extension; Risperdal®,Notice,General Notice,1994-10-27T04:00:00Z,1994,10,1994-10-27T04:00:00Z,1994-11-01T04:59:59Z,2024-05-23T16:08:19Z,,0,0,09000064804ff746
FDA-1993-N-0043-0009,FDA,FDA-1993-N-0043,Background Material,Supporting & Related Material,BKG-Background Material,1994-10-26T04:00:00Z,1994,10,,,2008-05-16T23:24:08Z,,0,0,09000064804fc45c
FDA-1993-N-0043-0011,FDA,FDA-1993-N-0043,Background Material,Supporting & Related Material,BKG-Background Material,1994-10-26T04:00:00Z,1994,10,,,2008-05-16T23:24:08Z,,0,0,09000064804fc45e
FDA-1993-N-0043-0008,FDA,FDA-1993-N-0043,Background Material,Supporting & Related Material,BKG-Background Material,1994-10-26T04:00:00Z,1994,10,,,2008-05-16T23:24:10Z,,0,0,09000064804fc45b
FDA-1993-N-0043-0012,FDA,FDA-1993-N-0043,Background Material,Supporting & Related Material,BKG-Background Material,1994-10-26T04:00:00Z,1994,10,,,2008-05-16T23:24:10Z,,0,0,09000064804fc45f
FDA-1993-N-0043-0010,FDA,FDA-1993-N-0043,Background Material,Supporting & Related Material,BKG-Background Material,1994-10-26T04:00:00Z,1994,10,,,2008-05-16T23:24:09Z,,0,0,09000064804fc45d
FDA-1981-N-0012-0011,FDA,FDA-1981-N-0012,"HFA-305 to Caprice-Greystoke, Ltd",Other,ACK-Acknowledgement Letter,1994-10-24T04:00:00Z,1994,10,,,2008-05-30T22:53:23Z,,0,0,09000064805ae8d6
FDA-1994-P-0013-0009,FDA,FDA-1994-P-0013,Acknowledgment Letter from FDA DMB to Minnesota Cultivated Wild Rice Council,Other,Acknowledgement Letter/Receipt,1994-10-18T04:00:00Z,1994,10,,,2024-06-27T03:41:49Z,,0,0,09000064804fc7e5
FDA-1978-N-0018-0135,FDA,FDA-1978-N-0018,Letter from FDA CDER to Arlington Dermatology Clinic South,Other,Letter(s),1994-10-17T04:00:00Z,1994,10,,,2019-07-22T16:53:28Z,,0,0,090000648055a1d7
FDA-1975-N-0012-0049,FDA,FDA-1975-N-0012,Request for Extension from Amway Corporation,Other,Request for Extension,1994-10-13T04:00:00Z,1994,10,,,2017-11-20T17:41:08Z,,0,0,09000064805c1947
FDA-1994-M-0011-0003,FDA,FDA-1994-M-0011,"Approval Letter from FDA CDRH to Exogen, Inc.",Other,Approval,1994-10-05T04:00:00Z,1994,10,,,2024-06-07T15:10:49Z,,0,0,09000064804fc71e
FDA-1994-P-0034-0001,FDA,FDA-1994-P-0034,HFA-305 to Reeves & Graddy,Other,ACK-Acknowledgement Letter,1994-09-27T04:00:00Z,1994,9,,,2008-05-16T23:19:11Z,,0,0,09000064804fd60a
FDA-1993-D-0019-0001,FDA,FDA-1993-D-0019,FDA,Notice,NAD-Notice of Availability of Data,1994-09-27T04:00:00Z,1994,9,,,2008-05-16T23:22:51Z,,0,0,09000064804fa914
FDA-1978-N-0018-0133,FDA,FDA-1978-N-0018,"Letter from FDA CDER to Person & Covey, Inc.",Other,Letter(s),1994-09-15T04:00:00Z,1994,9,,,2019-07-22T15:37:29Z,,0,0,090000648055a1c0
FDA-1985-V-0043-0001,FDA,FDA-1985-V-0043,FDA/CDRH,Other,LET-Letter,1994-09-12T04:00:00Z,1994,9,,,2008-05-30T22:53:19Z,,0,0,09000064805b5d16
FDA-1978-N-0018-0132,FDA,FDA-1978-N-0018,"Memorandum of Telephone Conversation between Arent, Fox, Kintner, Plotkin & Kahn and FDA/CDER, August 22, 1994",Other,Memorandum,1994-09-06T04:00:00Z,1994,9,,,2019-08-02T14:52:14Z,,0,0,090000648055a19c
FDA-1976-N-0027-0004,FDA,FDA-1976-N-0027,Notice of Final Rule re Partial Stay of Regulation; Enforcement Policy,Notice,Notice of Final Rule,1994-08-25T04:00:00Z,1994,8,,,2015-10-29T20:26:59Z,,0,0,090000648051b679
FDA-1994-M-0032-0001,FDA,FDA-1994-M-0032,"Cardiac Pacemakers, Inc., Premarket Approval of VENTAK@ PRx@ Model 1700 and Model 1705 AICD Tm System, Model 2850 PRESCRIPTOR TM Programmer and Model 2860 Program Disk",Notice,Notice of Approval,1994-08-16T04:00:00Z,1994,8,1994-08-16T04:00:00Z,1994-09-15T03:59:59Z,2024-06-03T15:59:13Z,,0,0,09000064804fd418
FDA-1994-G-0039-0004,FDA,FDA-1994-G-0039,Background Material re Captrin for Use as a Fat in Foods for Human Consumption,Supporting & Related Material,Background Material,1994-08-11T04:00:00Z,1994,8,,,2016-04-15T14:49:10Z,,0,0,09000064804fd8fe
FDA-1994-G-0039-0002,FDA,FDA-1994-G-0039,Background Material re Captrin for Use as a Fat in Foods for Human Consumption,Supporting & Related Material,Background Material,1994-08-11T04:00:00Z,1994,8,,,2016-04-15T14:50:22Z,,0,0,09000064804fd8eb
FDA-1994-G-0039-0001,FDA,FDA-1994-G-0039,Notice of Filing re Safe Use In Food Triglyceride Containing Caprylic & Capric,Notice,Notice of Filing,1994-08-11T04:00:00Z,1994,8,1994-08-11T04:00:00Z,1994-10-05T03:59:59Z,2016-04-08T19:06:48Z,,0,0,09000064804fd8c3
FDA-1994-G-0039-0003,FDA,FDA-1994-G-0039,Background Material re Captrin for Use as a Fat in Foods for Human Consumption,Supporting & Related Material,Background Material,1994-08-11T04:00:00Z,1994,8,,,2016-04-15T14:30:39Z,,0,0,09000064804fd8fb
FDA-1978-N-0018-0130,FDA,FDA-1978-N-0018,"Internal Memorandum from Director Monograph Review Staff (HFD-810) to Dockets Management Branch (HFA-305) August 3, 1994 re: Comment from Canadian Dermatology Association",Supporting & Related Material,Comment(s),1994-08-08T04:00:00Z,1994,8,,,2019-08-02T16:35:11Z,,0,0,090000648055a16d
FDA-1994-P-0005-0001,FDA,FDA-1994-P-0005,Acknowledgment Letter from FDA DMB to The Sugar Association,Other,Acknowledgement Letter/Receipt,1994-08-03T04:00:00Z,1994,8,,,2024-07-01T13:54:19Z,,0,0,09000064804fc55a
FDA-1994-P-0012-0009,FDA,FDA-1994-P-0012,"HFA-305 to Bass & Ullman, P. C.",Other,ACK-Acknowledgement Letter,1994-07-28T04:00:00Z,1994,7,,,2008-05-16T23:18:51Z,,0,0,09000064804fc786
FDA-1994-P-0012-0010,FDA,FDA-1994-P-0012,"HFA-305 to Bass & Ullman, P. C.",Other,ACK-Acknowledgement Letter,1994-07-28T04:00:00Z,1994,7,,,2008-05-16T23:18:51Z,,0,0,09000064804fc787
FDA-1978-N-0018-0129,FDA,FDA-1978-N-0018,"Correction to Memorandum of Meeting between FDA/CDER, et al., and Givauden-Roure Corporation, et al., May 11, 1994 from FDA/CDER",Other,Correction(s),1994-07-28T04:00:00Z,1994,7,,,2019-07-23T15:57:14Z,,0,0,090000648055a12c
FDA-1978-N-0018-0459,FDA,FDA-1978-N-0018,"Acknowledgment Letter from FDA/DDM to Arent Fox Kintner Plotkin & Kahn on behalf of Estee Lauder, Inc.",Other,Acknowledgement Letter/Receipt,1994-07-28T04:00:00Z,1994,7,,,2019-07-23T15:01:45Z,,0,0,090000648055a8b8
FDA-1978-N-0018-0128,FDA,FDA-1978-N-0018,Letter from FDA/CDER to Ivy Laboratories,Other,Letter(s),1994-07-27T04:00:00Z,1994,7,,,2019-07-22T18:55:33Z,,0,0,090000648055a126
FDA-1992-N-0056-0004,FDA,FDA-1992-N-0056,"Notice of Extension re Prescription Drug Marketing Act of 1987, Drug Amendments of 1992; Policies, Requirements, and Administrative Procedures; Reopening of Comment Period",Notice,Notice of Extension,1994-07-25T04:00:00Z,1994,7,1994-07-25T04:00:00Z,1994-08-16T03:59:59Z,2017-08-04T13:26:56Z,,0,0,090000648052bf07
FDA-1994-M-0008-0001,FDA,FDA-1994-M-0008,Allergan Medical Optics; Premarket Approval of the Model PC-28LB Ultraviolet-Absorbing Posterior Chamber Intraocular Lens,Notice,Notice of Approval,1994-07-21T04:00:00Z,1994,7,1994-07-21T04:00:00Z,1994-08-18T03:59:59Z,2024-05-28T11:53:44Z,94-17374,0,0,09000064804fc60a
FDA-1978-N-0018-0127,FDA,FDA-1978-N-0018,Letter from FDA/CDER to Temple University Medical Practices,Other,Letter(s),1994-07-19T04:00:00Z,1994,7,,,2019-07-22T18:26:46Z,,0,0,090000648055a11b
FDA-1994-P-0028-0001,FDA,FDA-1994-P-0028,Acknowledgment Letter from FDA DDM to Mckenna & Cuneo,Other,Acknowledgement Letter/Receipt,1994-07-12T04:00:00Z,1994,7,,,2017-10-07T21:38:33Z,,0,0,09000064804fd339
FDA-1986-D-0038-0009,FDA,FDA-1986-D-0038,FDA,Notice,NAD-Notice of Availability of Data,1994-07-08T04:00:00Z,1994,7,,,2008-05-30T22:52:43Z,,0,0,090000648050e78f
FDA-1986-D-0038-0008,FDA,FDA-1986-D-0038,FDA,Notice,NAD-Notice of Availability of Data,1994-07-08T04:00:00Z,1994,7,,,2008-05-30T22:52:51Z,,0,0,090000648050e78e
FDA-1975-N-0016-0021,FDA,FDA-1975-N-0016,Letter from FDA CDER to Ciba-Geigy Corporation,Other,Letter(s),1994-07-08T04:00:00Z,1994,7,,,2017-09-25T19:36:18Z,,0,0,09000064805c2277
FDA-1986-D-0038-0010,FDA,FDA-1986-D-0038,FDA,Notice,NAD-Notice of Availability of Data,1994-07-08T04:00:00Z,1994,7,,,2008-05-30T22:52:58Z,,0,0,090000648050e790
FDA-1978-N-0018-0125,FDA,FDA-1978-N-0018,"Memorandum of Meeting between FDA/CDER, et al., and Givauden-Roure Corporation, et al., May 11, 1994",Other,Memorandum,1994-07-07T04:00:00Z,1994,7,,,2019-07-22T17:58:20Z,,0,0,090000648055a116
FDA-1994-P-0040-0001,FDA,FDA-1994-P-0040,Acknowledgment Letter from FDA DMB to Tortilla Industry Association,Other,ACK-Acknowledgement Letter,1994-06-30T04:00:00Z,1994,6,,,2024-07-30T01:01:05Z,,0,0,09000064804fd9ce
FDA-1978-N-0018-0124,FDA,FDA-1978-N-0018,Letter from FDA CDER to King & Spaulding,Other,Letter(s),1994-06-30T04:00:00Z,1994,6,,,2019-07-29T18:43:55Z,,0,0,090000648055a10e
FDA-1978-N-0018-0123,FDA,FDA-1978-N-0018,"Memorandum of Meeting between FDA/CDER, Dr. Madhu Pathak, et al., and Givaudan-Roure Corporation, et al., May 12, 1994",Other,Memorandum,1994-06-30T04:00:00Z,1994,6,,,2019-09-04T17:19:22Z,,0,0,090000648055a10b
FDA-1994-M-0056-0001,FDA,FDA-1994-M-0056,"Sigmedics, Inc.; Premarket Approval of Parastep I System",Notice,Notice of Approval,1994-06-17T04:00:00Z,1994,6,1994-06-17T04:00:00Z,1994-07-15T03:59:59Z,2024-05-28T12:29:52Z,94-14315,0,0,090000648050388e
FDA-1994-F-0057-0001,FDA,FDA-1994-F-0057,Great Lakes Chemical Corp.; Filing of Food Additive Petition,Notice,Notice of Filing,1994-06-17T04:00:00Z,1994,6,1994-06-17T04:00:00Z,1994-07-15T03:59:59Z,2024-05-24T15:57:09Z,94-14371,0,0,09000064805038b0
FDA-1993-E-0006-0001,FDA,FDA-1993-E-0006,FDA,Notice,N-Notice,1994-06-17T04:00:00Z,1994,6,1994-06-17T04:00:00Z,1994-08-16T03:59:59Z,2008-05-16T23:23:12Z,,0,0,09000064804f9b7e
FDA-1975-N-0012-0044,FDA,FDA-1975-N-0012,Topical Antimicrobial Drug Products for Over-the Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,Proposed Rule,Notice of Proposed Rulemaking (NPRM),1994-06-16T04:00:00Z,1994,6,1994-06-16T04:00:00Z,1994-12-15T04:59:59Z,2017-10-16T12:01:00Z,94-14503,0,0,09000064805c190b
FDA-1994-N-0037-0001,FDA,FDA-1994-N-0037,FDA,Notice,NI-Notice of Intent,1994-06-15T04:00:00Z,1994,6,1994-06-15T04:00:00Z,1994-08-18T03:59:59Z,2008-05-16T23:15:38Z,,0,0,09000064804fd7ca
FDA-1978-N-0018-0122,FDA,FDA-1978-N-0018,Sunscreen Drug Products for Over-The-Counter Human Use; Proposed Amendment to the Tentative Final Monograph; Reopening of Comment Period,Notice,Notice of Extension,1994-06-14T04:00:00Z,1994,6,1994-06-14T04:00:00Z,1994-08-23T03:59:59Z,2019-07-19T19:49:02Z,94-13933,0,0,090000648055a108
FDA-1994-P-0012-0008,FDA,FDA-1994-P-0012,"HFA-305 to Akin, Gump, Strauss, Hauer & Feld, L. L. P.",Other,ACK-Acknowledgement Letter,1994-06-09T04:00:00Z,1994,6,,,2008-05-16T23:18:51Z,,0,0,09000064804fc785
FDA-1992-N-0017-0005,FDA,FDA-1992-N-0017,FDA,Notice,NFR-Notice of Final Rule,1994-06-01T04:00:00Z,1994,6,,,2008-05-16T23:32:01Z,,0,0,0900006480526aaf
FDA-1992-N-0017-0002,FDA,FDA-1992-N-0017,FDA,Notice,NFR-Notice of Final Rule,1994-06-01T04:00:00Z,1994,6,,,2008-05-16T23:32:01Z,,0,0,0900006480526aa6
FDA-1992-N-0017-0006,FDA,FDA-1992-N-0017,FDA,Notice,NFR-Notice of Final Rule,1994-06-01T04:00:00Z,1994,6,,,2008-05-16T23:32:00Z,,0,0,0900006480526ab4
FDA-1994-M-0009-0001,FDA,FDA-1994-M-0009,OrthoLogic Corp.; Premarket Approval of Orthologic 1000,Notice,Notice of Approval,1994-06-01T04:00:00Z,1994,6,,,2024-05-28T13:34:36Z,94-12374,0,0,09000064804fc625
FDA-1992-N-0017-0004,FDA,FDA-1992-N-0017,FDA,Notice,NFR-Notice of Final Rule,1994-06-01T04:00:00Z,1994,6,,,2008-05-16T23:32:01Z,,0,0,0900006480526aac
FDA-1992-N-0017-0003,FDA,FDA-1992-N-0017,FDA,Notice,NFR-Notice of Final Rule,1994-06-01T04:00:00Z,1994,6,,,2008-05-16T23:32:01Z,,0,0,0900006480526aa9
FDA-1992-E-0012-0002,FDA,FDA-1992-E-0012,Determination of Regulatory Review Period for Purposes of Patent Extension; Supprelin; Correction,Notice,Correction,1994-05-26T04:00:00Z,1994,5,,,2023-09-25T11:46:30Z,94-9047,0,0,0900006480526109
FDA-1980-N-0057-0012,FDA,FDA-1980-N-0057,"Petition Denial Letter from FDA (HFC-1) to Alcon Laboratories, Inc.",Other,Denial,1994-05-26T04:00:00Z,1994,5,,,2022-03-23T18:44:49Z,,0,0,09000064805ba5c0
FDA-1994-P-0002-0002,FDA,FDA-1994-P-0002,Acknowledgment Letter from FDA DMB to Food Marketing Institute,Other,Acknowledgement Letter/Receipt,1994-05-20T04:00:00Z,1994,5,,,2024-06-24T17:30:16Z,,0,0,09000064804fc4b4
FDA-1993-N-0057-0026,FDA,FDA-1993-N-0057,FDA,Notice,NEC-Notice of Extension,1994-05-19T04:00:00Z,1994,5,1994-05-19T04:00:00Z,1994-08-04T03:59:59Z,2008-05-16T23:24:17Z,,0,0,09000064804fc6c1
FDA-1993-N-0013-0007,FDA,FDA-1993-N-0013,FDA,Notice,NEC-Notice of Extension,1994-05-19T04:00:00Z,1994,5,1994-05-19T04:00:00Z,1994-06-04T03:59:59Z,2008-05-16T23:23:57Z,,0,0,09000064804fa495
FDA-1993-P-0034-0001,FDA,FDA-1993-P-0034,Petition Denial Response Letter from FDA ORA to The Foundation on Economic Trends,Other,Denial of Petition,1994-05-19T04:00:00Z,1994,5,,,2017-06-19T15:08:07Z,,0,0,09000064804fb940
FDA-1978-N-0018-0120,FDA,FDA-1978-N-0018,Letter from FDA/CDER to King & Spalding,Other,Letter(s),1994-05-12T04:00:00Z,1994,5,,,2019-07-22T18:47:28Z,,0,0,090000648055a020
FDA-1993-N-0057-0027,FDA,FDA-1993-N-0057,Background Material,Supporting & Related Material,BKG-Background Material,1994-05-04T04:00:00Z,1994,5,,,2008-05-16T23:24:16Z,,0,0,09000064804fc71d
FDA-1982-P-0018-0387,FDA,FDA-1982-P-0018,Acknowledgement Letter from FDA Dockets Management Branch to Edward R. Hutchinson,Other,Acknowledgement Letter/Receipt,1994-05-03T04:00:00Z,1994,5,,,2025-01-06T15:53:08Z,,0,0,090000648050e72a
FDA-1994-M-0019-0001,FDA,FDA-1994-M-0019,"Medtronic, Inc.; Premarket Approval of the Medtronic® Transvene® Lead System",Notice,NAL-Notice of Approval,1994-04-28T04:00:00Z,1994,4,1994-04-28T04:00:00Z,1994-05-20T03:59:59Z,2009-01-29T18:57:08Z,,0,0,09000064804fcb03
FDA-1992-N-0056-0003,FDA,FDA-1992-N-0056,Envelope re Comment from Pharmaceutical Manufacturers Association,Supporting & Related Material,Transmittals,1994-04-26T04:00:00Z,1994,4,,,2016-03-15T14:29:57Z,,0,0,090000648052be8e
FDA-1992-N-0056-0001,FDA,FDA-1992-N-0056,"Notice of Proposed Rulemaking re Prescription Drug Marketing Act of 1987, Drug Amendments of 1992",Proposed Rule,NPR-Notice of Proposed Rule-Making,1994-04-26T04:00:00Z,1994,4,1994-04-26T04:00:00Z,1994-05-31T03:59:59Z,2017-08-05T19:09:08Z,,0,0,090000648052be86
FDA-1994-M-0046-0001,FDA,FDA-1994-M-0046,"DePuy, Inc.; Premarket Approval of the Rotating Platform Configuration of the New Jersey LCSB Total Knee System",Notice,Notice of Approval,1994-04-26T04:00:00Z,1994,4,1994-04-26T04:00:00Z,1994-05-19T03:59:59Z,2024-06-04T13:21:46Z,,0,0,09000064804ff6ee
FDA-1992-N-0056-0002,FDA,FDA-1992-N-0056,"Notice of Proposed Rulemaking re Prescription Drug Marketing Act of 1987, Drug Amds of 1992",Proposed Rule,Notice of Proposed Rulemaking (NPRM),1994-04-26T04:00:00Z,1994,4,1994-04-26T04:00:00Z,1994-05-31T03:59:59Z,2016-03-15T14:00:22Z,,0,0,090000648052be8c
FDA-1981-N-0043-0008,FDA,FDA-1981-N-0043,Acknowledgment Letter from FDA DMS to Nonprescription Drug Manufacturers Association,Other,Acknowledgement Letter/Receipt,1994-04-25T04:00:00Z,1994,4,,,2021-03-15T13:37:42Z,,0,0,09000064805af2fa
FDA-1994-P-0015-0002,FDA,FDA-1994-P-0015,Acknowledgment Letter from FDA DMB to Kleinfeld Kaplan & Becker,Other,Acknowledgement Letter/Receipt,1994-04-14T04:00:00Z,1994,4,,,2024-07-29T15:37:51Z,,0,0,09000064804fc971
FDA-1994-P-0015-0001,FDA,FDA-1994-P-0015,Acknowledgment Letter from FDA DMB to Kleinfeld Kaplan & Becker,Other,Acknowledgement Letter/Receipt,1994-04-14T04:00:00Z,1994,4,,,2024-07-29T15:24:07Z,,0,0,09000064804fc904
FDA-1994-P-0048-0001,FDA,FDA-1994-P-0048,Acknowledgment Letter from FDA DMB to Glaxo Inc.,Other,Acknowledgement Letter/Receipt,1994-04-13T04:00:00Z,1994,4,,,2024-06-18T13:27:13Z,,0,0,09000064804ff83a
FDA-1992-E-0012-0003,FDA,FDA-1992-E-0012,"Acknowledgement Letter from FDA Dockets Management Branch to Fitch, Even, Tabin & Flannery",Other,Acknowledgement Letter/Receipt,1994-04-08T04:00:00Z,1994,4,,,2023-09-25T11:57:36Z,,0,0,090000648052610d
FDA-1978-N-0021-0004,FDA,FDA-1978-N-0021,Tab B: Supporting & related materials,Supporting & Related Material,Background Material,1994-04-07T04:00:00Z,1994,4,,,2016-09-16T16:55:56Z,,0,0,090000648055d115
FDA-1978-N-0021-0006,FDA,FDA-1978-N-0021,Tab A: Products complaints and published materials,Supporting & Related Material,Background Material,1994-04-07T04:00:00Z,1994,4,,,2016-09-16T16:55:21Z,,0,0,090000648055d11d
FDA-1978-N-0021-0005,FDA,FDA-1978-N-0021,Notice of Proposed Rulemaking -Laxative Drug Products For Over-The-Counter Human Use; Proposed Amendment To The Tentative Final Monograph,Proposed Rule,Notice of Proposed Rulemaking (NPRM),1994-04-07T04:00:00Z,1994,4,1994-04-07T04:00:00Z,1994-06-01T03:59:59Z,2016-08-03T19:58:19Z,,0,0,090000648055d119
FDA-1978-N-0018-0117,FDA,FDA-1978-N-0018,Answer Letter from FDA/CDER to Dr. Beverly Summers,Other,Letter(s),1994-04-06T04:00:00Z,1994,4,,,2019-07-22T12:23:19Z,,0,0,0900006480559fad
FDA-1978-N-0018-0119,FDA,FDA-1978-N-0018,Answer Letter from FDA/CDER to Nicholas J. Lowe,Other,Letter(s),1994-04-06T04:00:00Z,1994,4,,,2019-07-22T12:32:57Z,,0,0,0900006480559fd3
FDA-1978-N-0018-0118,FDA,FDA-1978-N-0018,Answer Letter from FDA/CDER to James L. Boren,Other,Letter(s),1994-04-06T04:00:00Z,1994,4,,,2019-07-22T12:28:04Z,,0,0,0900006480559fb4